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Background
The rate of death, including sudden cardiac death, is highest early after a myocar-
dial infarction. Yet current guidelines do not recommend the use of an implantable 
cardioverter–defibrillator (ICD) within 40 days after a myocardial infarction for the 
prevention of sudden cardiac death. We tested the hypothesis that patients at in-
creased risk who are treated early with an ICD will live longer than those who receive 
optimal medical therapy alone.
Methods
This randomized, prospective, open-label, investigator-initiated, multicenter trial 
registered 62,944 unselected patients with myocardial infarction. Of this total, 898 
patients were enrolled 5 to 31 days after the event if they met certain clinical criteria: 
a reduced left ventricular ejection fraction (≤40%) and a heart rate of 90 or more 
beats per minute on the first available electrocardiogram (ECG) (criterion 1: 602 pa-
tients), nonsustained ventricular tachycardia (≥150 beats per minute) during Holter 
monitoring (criterion 2: 208 patients), or both criteria (88 patients). Of the 898 pa-
tients, 445 were randomly assigned to treatment with an ICD and 453 to medical 
therapy alone.
Results
During a mean follow-up of 37 months, 233 patients died: 116 patients in the ICD 
group and 117 patients in the control group. Overall mortality was not reduced in 
the ICD group (hazard ratio, 1.04; 95% confidence interval [CI], 0.81 to 1.35; P = 0.78). 
There were fewer sudden cardiac deaths in the ICD group than in the control group 
(27 vs. 60; hazard ratio, 0.55; 95% CI, 0.31 to 1.00; P = 0.049), but the number of non-
sudden cardiac deaths was higher (68 vs. 39; hazard ratio, 1.92; 95% CI, 1.29 to 2.84; 
P = 0.001). Hazard ratios were similar among the three groups of patients categorized 
according to the enrollment criteria they met (criterion 1, criterion 2, or both).
Conclusions
Prophylactic ICD therapy did not reduce overall mortality among patients with 
acute myocardial infarction and clinical features that placed them at increased risk. 
(ClinicalTrials.gov number, NCT00157768.)
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Despite the general improvement in outcomes among survivors of acute myocardial infarction the rate of death, 
including sudden cardiac death, remains highest 
in the weeks after the event.1,2 Sudden cardiac 
death due to ventricular tachyarrhythmias ac-
counts for approximately 20 to 50% of all deaths 
in this population.3-5 Therefore, prevention of 
sudden cardiac death after myocardial infarction 
remains an important goal. With the exception 
of beta-blockers, antiarrhythmic drugs do not re-
duce this risk. Several randomized trials have 
shown that an implantable cardioverter–defibril-
lator (ICD) can reduce mortality both among pa-
tients who have had sustained ventricular tachy-
arrhythmias6 and among selected patients who 
have a depressed left ventricular ejection fraction 
(LVEF) without ventricular arrhythmias.7,8 How-
ever, guidelines based on the results of these trials 
— including one that showed a neutral effect of 
defibrillator implantation early after myocardial 
infarction9 — recommend that implantation of 
an ICD for the primary prevention of sudden death 
be withheld for at least 40 days after an acute 
myocardial infarction.
The Immediate Risk Stratification Improves 
Survival (IRIS) trial was based on the hypothesis 
that early implantation of an ICD, as compared 
with optimal medical therapy, would improve 
survival among patients with acute myocardial 
infarction and predefined markers of elevated 
risk. LVEF, heart rate (as determined on the ad-
mission electrocardiogram [ECG]), and the occur-
rence of rapid, nonsustained ventricular tachy-
cardia were the factors used to determine each 
patient’s level of risk.3,10-16
Me thods
Patient Population and Randomization
Between June 9, 1999, and October 15, 2007, the 
records of 62,944 patients who had an acute 
myocardial infarction with or without ST-segment 
elevation were collected in a registry from which 
our study population would be derived. Exclusion 
criteria consisted of the presence of ventricular 
arrhythmias that occurred before the index in-
farction or more than 48 hours after the event 
and that required treatment, New York Heart As-
sociation (NYHA) class IV drug-refractory heart 
failure, an interval of more than 31 days between 
myocardial infarction and presentation, no ECG 
documentation within the first 48 hours after the 
onset of chest pain, an indication for coronary-
artery bypass surgery before study entry, a psychi-
atric disorder, severe concomitant disease, a his-
tory of poor compliance with treatment, either 
the inability to participate in this trial or current 
participation in another trial, and an unstable 
clinical condition. After 26,445 patients had been 
excluded on the basis of these criteria, 36,499 were 
screened for inclusion.
Patients had to meet at least one of two crite-
ria for inclusion. Criterion 1 was a heart rate of 
90 beats per minute or more on the first avail-
able ECG (obtained within 48 hours after the myo-
cardial infarction) and an LVEF of 40% or less 
(on one of days 5 to 31 after myocardial infarc-
tion). Criterion 2 was nonsustained ventricular 
tachycardia consisting of three or more consecu-
tive ventricular premature beats during Holter 
ECG monitoring, with a heart rate of 150 beats 
per minute or more (on days 5 to 31).
A total of 1311 eligible patients, 18 to 80 years 
of age, met one or both criteria for inclusion in 
the study; 409 patients declined to participate, 
and written consent was missing for 4. The re-
maining 898 patients (86% of whom were still in 
the hospital) were randomly assigned to a study 
treatment — 445 to receive an ICD and 453 to 
receive medical therapy alone — at a mean (±SD) 
of 13±7 days after infarction.
Study Design
The primary objective of IRIS was to assess over-
all mortality in the two patient groups; second-
ary end points included sudden cardiac death, 
nonsudden cardiac death, and noncardiac death. 
The design of this European investigator-initiat-
ed trial has been described previously.17 A group-
sequential design according to O’Brien and Flem-
ing,18 with three interim analyses, after 50, 100, 
and 150 events, was selected initially and was 
described in the study protocol. However, in its 
first session, the data and safety monitoring board 
advised us to replace this strategy with the cor-
responding Lan–DeMets approach,19,20 which is 
based on the same alpha-spending function, to 
allow deviations from the fixed numbers of events. 
On January 9, 2005, this change was made as an 
addendum to the protocol. 
The study protocol was approved by the local 
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ethics committees at all 92 participating centers, 
and all the patients provided written informed 
consent. To increase recruitment, two modifica-
tions were made during the course of the study: 
patients with non–ST-elevation myocardial infarc-
tion were included as of June 1, 2002; and the 
qualifying heart rate on the first available ECG 
as part of criterion 1 was reduced from 100 or 
more to 90 or more beats per minute beginning 
on October 14, 2004.
Of the patients randomly assigned to the ICD 
group, 78% received Medtronic models of the 
GEM family, 11% Micro Jewel II, 8% Maximo, 
and 3% Marquis. Of this group, 81% received a 
single-chamber ICD, and a Fidelis lead was used 
in 21% of the patients. The protocol required two 
consecutive terminations of ventricular fibrilla-
tion at 10 J below the maximum ICD output and 
single-chamber ventricular demand (VVI) pacing 
at 40 beats per minute, with maximal shock 
energy turned on for treatment of ventricular 
fibrillation (threshold for treatment, ≥200 beats 
per minute) and treatment for ventricular tachy-
cardia turned off initially.
After discharge, patients were followed at in-
tervals of 3 and 6 months after randomization 
and at 6-month intervals thereafter.
The academic authors designed the trial, col-
lected and analyzed the data, and wrote the re-
port. The sponsors (Medtronic and AstraZeneca) 
were informed about the study outcome after the 
evaluation had been completed. Apart from an 
opportunity to review and provide comments 
about the predefined final-analysis plan and the 
manuscript, neither sponsor had a role in the 
study design, data analysis, or interpretation of 
the results.
Classification of Deaths
An adverse-event committee that was unaware of 
the treatment assignments classified the 233 fatal 
events as definitely cardiac (148 cases), unknown 
(46 cases), or definitely noncardiac (39 cases) and 
as sudden or nonsudden. For the purpose of 
analysis, patients whose events were classified as 
both definitely cardiac and unknown were com-
bined under the category of presumably cardiac 
death. A death, either in the hospital or out of the 
hospital, was assumed to be a sudden cardiac 
death if a cardiac death occurred within minutes 
after the onset of acute symptoms, resulted from 
a documented cardiac arrhythmia, or was not wit-
nessed and occurred unexpectedly and without 
recognizable causes (e.g., during sleep). Further-
more, a death was classified as a sudden cardiac 
death regardless of the underlying condition.
Statistical Analysis
According to the plan decided upon before un-
blinding, data collection and statistical analysis 
were executed by Oncology Services Europe, an 
independent data-coordinating center, which used 
SAS software, version 9.1.3. Statistical analysis 
was independently repeated by one of the authors 
with full access to the data. Subdistribution haz-
ard analyses were performed using R software 
(cmprsk package), and baseline comparisons were 
carried out by means of Fisher’s exact tests, chi-
square tests, or Wilcoxon tests, as appropriate. 
The primary analysis was performed on an inten-
tion-to-treat basis and included all randomized 
patients from whom written informed consent 
had been obtained. The cumulative risks of death 
from any cause were estimated separately for each 
treatment group with the use of the Kaplan–
Meier procedure21 and were compared between 
groups with the use of the log-rank test.22 Cumu-
lative mortality by year and annual rates were 
calculated with the use of an inverse Kaplan–
Meier analysis.
For sample-size calculation, 2-year survival 
rates were assumed to be 70.6% in the control 
group and 79.4% in the ICD group (a relative-
risk reduction of approximately 30% in the latter 
group). To calculate the required number of pa-
tients, we assumed an alpha error of 5% (two-
sided), a beta error of 20%, a 30-month recruit-
ment period, and a minimum follow-up of 2 years. 
With a lost-to-follow-up rate of 1% per year and 
taking into account the group-sequential design, 
the required number of patients in each thera-
py group was 350. Because the percentage of 
screened patients who were excluded was unex-
pectedly high, the recruitment time was more 
than doubled.
On December 13, 2005, because of a lower-
than-expected mortality rate, the data and safety 
monitoring board advised us to increase the num-
ber of patients to 900 and to extend follow-up 
until the last patient had been in the study for 
1 year. These changes were agreed to by the steer-
ing committee, and the group-sequential pro-
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cedure was adapted by replacing the fixed 
O’Brien and Fleming strategy by a Lan–DeMets 
approach.19,20 However, the alpha-spending func-
tion was not changed. The final primary analy-
sis was performed with the use of ADDPLAN, 
version 4.0.23
Calculation of hazard ratios and subgroup 
analyses with respect to the primary end point 
were performed on the basis of Cox proportional-
hazards models. The proportional-hazards as-
sumption was tested on the basis of Schoenfeld 
residuals. Subgroup analyses were performed one 
by one, with the use of the corresponding inter-
action test for comparison of the treatment effect 
between subgroups. Thirteen subgroup analyses 
were prespecified, and one post hoc subgroup 
analysis was added (for the effect of amiodarone). 
Two of these subgroup analyses (NYHA class 
and use or nonuse of amiodarone) involved in-
formation collected at discharge and thus were 
based on data from the patients who were still 
in the study when they left the hospital.
Since the causes of death represented com-
peting risks, introducing bias in the Kaplan–
Meier analysis, these were analyzed on the basis 
of proportional-subdistribution-hazard models.24 
Table 1. Baseline Demographic and Clinical Characteristics of the Patients, According to Study Group.*
Characteristic
ICD Group 
(N = 445)
Control Group 
(N = 453)
Male sex — no. (%) 345 (77.5) 344 (75.9)
Age — yr 62.8±10.5 62.4±10.6
STEMI — no. (%) 341 (76.6) 348 (76.8)
Reperfusion in STEMI — no./total no. (%)
None 43/340 (12.6) 48/348 (13.8)
PTCA 243/340 (71.5) 253/348 (72.7)
Thrombolytic therapy, with or without PTCA 54/340 (15.9)  47/348 (13.5) 
Anterior-wall MI — no./total no. (%) 282/439 (64.2) 300/449 (66.8)
Heart failure on admission — no./total no. (%) 197/444 (44.4) 209/453 (46.1)
Previous MI — no./total no. (%) 77/444 (17.3) 89/453 (19.6)
Atrial fibrillation — no./total no. (%) 60/445 (13.5) 61/453 (13.5)
Diabetes mellitus — no./total no. (%) 165/444 (37.2) 137/453 (30.2)
Left bundle-branch block — no./total no. (%) 45/445 (10.1) 29/453 (6.4)
Hypertension — no./total no. (%) 296/444 (66.7) 300/453 (66.2)
Criteria for inclusion — no. (%)
Criterion 1 only 299 (67.2) 303 (66.9)
Criterion 2 only 99 (22.2) 109 (24.1)
Criteria 1 and 2 47 (10.6) 41 (9.1)
Left ventricular ejection fraction — % 34.6±9.3 34.5±9.4
Criterion 1 only 32.2±6.3 31.9±6.7
Criterion 2 only 45.9±10.8 44.8±11.0
Criteria 1 and 2 29.6±7.0 31.4±6.7
Medical therapy on admission — no./total no. (%)
Antiplatelet agents 438/443 (98.9) 442/452 (97.8)
Beta-blockers 394/442 (89.1) 388/453 (85.7)
ACE inhibitors 361/443 (81.5) 373/453 (82.3)
* Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, ICD implantable cardioverter–defibril-
lator, MI myocardial infarction, PTCA percutaneous transluminal coronary angiography, and STEMI ST-elevation myo-
cardial infarction.
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Hazard ratios for the subdistribution models 
and P values for interaction are reported in the 
same way as the results of the Cox proportional-
hazards models.
R esult s
The baseline demographic characteristics of the 
two randomized groups were well balanced, al-
though diabetes and left bundle-branch block 
were slightly more frequent in the ICD group 
(P = 0.03 and P = 0.05, respectively) (Table 1).
At discharge, the NYHA class could be as-
sessed in 885 of the surviving patients and was 
judged to be class I in 247 patients (28%), class 
II in 531 (60%), and class III in 106 (12%); the 
class changed to IV in 1 patient (0.1%). Discharge 
medications in the ICD group and the control 
group included beta-blockers (in 97.1% and 95.3% 
of patients, respectively), angiotensin-converting–
enzyme (ACE) inhibitors (90.9% and 91.1%), 
antiplatelet agents (96.1% and 95.8%), and statins 
(91.6% and 91.5%), whereas use of antiarrhyth-
mic drugs (mainly amiodarone) was slightly more 
frequent in the control group (17.4%, vs. 13.4% 
in the ICD group; P = 0.11).
Risk of Death and Effects of the ICD
Figure 1 shows the cumulative risk of death from 
any cause for the two patient groups. During an 
average follow-up of 37 months (range, 0 to 106), 
117 patients in the control group died and 116 
patients in the ICD group died. The cumulative 
death rates at 1, 2, and 3 years were 12.5%, 
18.2%, and 22.9%, respectively, in the control 
group and 10.6%, 15.4%, and 22.4%, respectively, 
in the ICD group. No significant difference in 
survival was detected between the two treatment 
groups (P = 0.76, and P = 0.78 after adjustment for 
interim analyses, by the log-rank test); the haz-
ard ratio for death in the ICD group was 1.04 (95% 
confidence interval [CI], 0.81 to 1.35; P = 0.15 by 
the test of proportional-hazards assumption).
Figure 2 shows the hazard ratios for subgroups 
of interest. As for the overall study population, a 
neutral effect of the ICD on overall mortality is 
seen in all three prespecified subgroups (patients 
meeting criterion 1 only, those meeting criterion 
2 only, and those meeting both criteria).
Figure 3 and Table 2 show the relationship 
between ICD therapy and the cause of death. 
There were fewer sudden cardiac deaths in the 
ICD group than in the control group (27 vs. 60) 
(hazard ratio, 0.55; 95% CI, 0.31 to 1.00; P = 0.049) 
(Fig. 3A). However, this decrease is paralleled by 
an increase in nonsudden cardiac death in the 
ICD group as compared with the control group 
(68 vs. 39) (hazard ratio, 1.92; 95% CI, 1.29 to 
2.84; P = 0.001) (Fig. 3B). The effects were almost 
identical in the three predefined subgroups of 
patients based on the inclusion criteria (interac-
tion, P = 0.99 or P = 0.71 for sudden or nonsudden 
cardiac death, respectively) (Table 2).
Compliance with Therapy and Adverse Events 
Related to ICD
Of the 445 patients in the ICD group, 415 actu-
ally received the ICD system. Thirty patients did 
not receive an ICD: 14 patients withdrew their 
consent, 11 refused ICD implantation, and 5 died 
before implantation could take place. In 378 pa-
tients (91.1%), implantation was performed dur-
ing the hospitalization for the index infarction. 
In one patient, the inserted lead became entan-
gled in the tricuspid valve and was removed sur-
gically. In 14 patients, the ICD was explanted or 
permanently deactivated during follow-up, at a 
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Figure 1. Cumulative Risk of Death from Any Cause According to Study 
Group.
At the close of the study, definitive information about vital status was avail-
able for 897 patients. One patient was lost to follow-up. For patients who 
withdrew their consent, data were censored at the time of withdrawal. ICD 
denotes implantable cardioverter–defibrillator.
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median of 6.8 months after implantation. In sum-
mary, at study termination there were 45 patients 
without an ICD, as opposed to 39 patients in the 
control group who received an ICD at a median 
of 7.6 months after randomization.
Of the 415 patients who received an ICD as 
assigned during the study, a total of 65 (15.7%) 
had 76 clinically significant complications associ-
ated with ICD therapy that required hospitaliza-
tion, surgical correction, or intravenous drug 
administration: in 19 patients (4.6%) during the 
post-implantation period (up to 30 days after 
implantation), and in 48 patients (11.6%) during 
follow-up. These complications included lead-
related problems that required surgical revision 
in 10 patients, 4 of whom underwent replacement 
of Fidelis leads.
Seven patients in the ICD group died during 
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Figure 2. Hazard Ratios for Death from Any Cause in Selected Subgroups of Patients.
Not included in the figure are hazard ratios for subgroups based on the presence or absence of diabetes, hyperten-
sion, and lipid abnormalities and on the number of risk factors (0 to 2 vs. 3 or 4, for diabetes, hypertension, smoking, 
and lipid abnormality), which were similar in the two study groups. ICD denotes implantable cardioverter–defibrillator, 
NYHA New York Heart Association, PTCA percutaneous transluminal coronary angiography, and STEMI ST-elevation 
myocardial infarction.
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the post-implantation period (within 30 days after 
implantation) owing to myocardial reinfarction 
in four patients and heart failure in three. One 
of them died during implantation. Within 30 days 
after randomization, 9 patients in the ICD group 
died, as compared with 11 patients in the con-
trol group.
Discussion
This large-scale, randomized study assessed the 
benefit of prophylactic ICD implantation early 
after myocardial infarction in a contemporary 
population. The majority of the patients (75%) had 
undergone reperfusion therapy (percutaneous 
trans luminal coronary angiography or thromboly-
sis) as well as optimal long-term medical therapy 
with beta-blockers, ACE inhibitors, statins, and 
antiplatelet drugs. For risk stratification, we used 
the following criteria: impaired left ventricular 
function associated with an increased heart rate, 
as well as rapid unsustained ventricular tachycar-
dia. Although average left ventricular function was 
better preserved in this study (ejection fraction, 
35%) than in other primary-prevention trials (e.g., 
23% in the Second Multicenter Automatic Defi-
brillator Implantation Trial [MADIT II], 25% in the 
Sudden Cardiac Death in Heart Failure Trial [SCD–
HeFT, ClinicalTrials.gov number, NCT00000609], 
and 28% in the Defibrillator in Acute Myocardial 
Infarction Trial [DINAMIT]), actual mortality was 
still substantial — that is, 23% at 3 years; never-
theless, ICD implantation did not convey a prog-
nostic advantage in our study. Thus, with differ-
ent risk markers, generating a larger population 
at risk, and a longer follow-up period, our trial 
confirms the results of DINAMIT.9 According to 
the calculated confidence interval for the corre-
sponding hazard ratio, risk reductions of up to 
19% in our trial (24% in DINAMIT) as well as 
risk increases of up to 35% (55% in DINAMIT) 
may have gone undetected.
With respect to the type of death, the ICD 
significantly reduced the rate of sudden cardiac 
death, which was counterbalanced by an increase 
in the rate of cardiac death from other causes, 
again confirming the findings in DINAMIT.9 It 
should be kept in mind that this categorization 
of deaths was done by an event committee on 
the basis of available data about the circum-
stances of death, but the committee members 
were unaware of the study-group assignments.
An increase in the rate of cardiac death other 
than sudden cardiac death might theoretically 
be caused by an imbalance in baseline character-
istics between the two randomized groups; com-
plications related to ICD implantation; the devel-
opment of heart failure due to ventricular pacing 
of the ICD; study-group crossovers; untoward 
effects of defibrillator shocks and antitachycar-
dia pacing; the substrate of acute myocardial 
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Figure 3. Cumulative Risk of Cardiac Death, According to Study Group.
The cumulative risk of sudden cardiac death is shown in Panel A, and the 
cumulative risk of nonsudden cardiac death is shown in Panel B. ICD de-
notes implantable cardioverter–defibrillator.
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infarction studied (i.e., rapid ventricular tachy-
cardia and fibrillation due to pump failure, which 
led to death anyway); other, unidentified side 
effects of the ICD; and between-group differences 
in the use of concomitant therapies.
Baseline characteristics were well balanced 
between the two groups, mortality at 1 month 
was similar, and backup ventricular pacing was 
programmed to 40 beats per minute; thus, the 
first three explanations seem unlikely. The rate 
of crossover from the ICD group to the control 
group was higher in our study (10.1% [45 of 445 
patients]) than in the SCD–HeFT (6.0%), where-
as the rate of crossover from the control group to 
the ICD group was somewhat lower in our study 
(8.6% [39 of 453 patients]) than in the SCD–
HeFT (11.1%).
A recent follow-up study of SCD–HeFT showed 
that although patients with heart failure have an 
overall benefit from prophylactic ICD implanta-
tion, those receiving shocks have a substantially 
increased risk of death.25 A similar, though less 
pronounced, effect of the ICD had also been re-
ported for MADIT II.26-28
The question of which mechanisms considered 
above might have contributed to the increased 
risk of nonsudden cardiac death in the ICD 
group in our study, as well as the extent of the 
contribution, remains unresolved.
With respect to risk stratification, in our total 
registry of 62,944 patients, the proportion of pa-
tients who met criterion 1 (LVEF ≤40% and heart 
rate on admission ≥90 beats per minute) and the 
proportion of patients who met criterion 2 (rapid, 
nonsustained ventricular tachycardia [≥150 beats 
per minute]) were very small (1.1% and 0.5%, 
respectively), accounting for the extension of the 
recruitment phase to 8 years.
The major reason for difficulties in conducting 
this study was the unanticipated and multifacto-
Table 2. Causes of Death in the Study Groups.*
Cause of Death ICD Group Control Group
Subdistribution 
Hazard Ratio
Unadjusted 
P Value
no./total no. (%)
All patients
Any cause 116/445 (26.1) 117/453 (25.8) 1.04 0.76
Sudden cardiac death 27/445 (6.1) 60/453 (13.2) 0.55 0.049
Nonsudden cardiac death 68/445 (15.3) 39/453 (8.6) 1.92 0.001
Noncardiac death 21/445 (4.7) 18/453 (4.0) 1.23 0.51
Patients meeting criterion 1 only 
Any cause 78/299 (26.1) 82/303 (27.1) 1.02 0.91
Sudden cardiac death 20/299 (6.7) 45/303 (14.9) 0.46 0.003
Nonsudden cardiac death 44/299 (14.7) 27/303 (8.9) 1.80 0.02
Noncardiac death 14/299 (4.7) 10/303 (3.3) 1.52 0.32
Patients meeting criterion 2 only 
Any cause 21/99 (21.2) 20/109 (18.3) 1.16 0.63
Sudden cardiac death 3/99 (3.0) 7/109 (6.4) 0.46 0.25
Nonsudden cardiac death 13/99 (13.1) 6/109 (5.5) 2.58 0.06
Noncardiac death 5/99 (5.1) 7/109 (6.4) 0.74 0.60
Patients meeting criteria 1 and 2
Any cause 17/47 (36.2) 15/41 (36.6) 0.84 0.62
Sudden cardiac death 4/47 (8.5) 8/41 (19.5) 0.36 0.08
Nonsudden cardiac death 11/47 (23.4) 6/41 (14.6) 1.53 0.39
Noncardiac death 2/47 (4.3) 1/41 (2.4) 1.50 0.72
* The data include all deaths during a follow-up period of up to 106 months (average, 37). ICD denotes implantable car-
dioverter–defibrillator.
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rial improvement in outcomes seen in contem-
porary unselected patient populations after myo-
cardial infarction.1,2,29 After hospital discharge of 
patients whose myocardial infarction is treated 
according to current guidelines, sudden cardiac 
death is not as great a threat as it once was.2
Risk stratification as applied in the IRIS trial 
has identified a subgroup of patients who are at 
increased risk for death, including sudden death, 
but who do not have a response to the early ini-
tiation of ICD therapy. Any further attempts to 
reduce the risk of sudden death with the use of 
more refined algorithms of identification (e.g., 
T-wave alternans30 or improved assessment of 
heart rate variability31), new treatment strategies 
beyond current guidelines, or both these ap-
proaches will probably face similar, major diffi-
culties with respect to study conduct and resourc-
es, as reported here for the IRIS trial.
In conclusion, we found no evidence that 
implantation of an ICD improved survival in pa-
tients with acute myocardial infarction who re-
ceived optimal medical therapy and underwent 
risk stratification based on elevated heart rate on 
admission, low LVEF, and rapid, nonsustained 
ventricular tachycardia. Although the risk of sud-
den cardiac death was reduced by ICD therapy, 
this effect was offset by an increase in the risk 
of nonsudden cardiac death — an observation 
that deserves further study.
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APPENDIX
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Wistorf; Oberschwaben-Klinik Krankenhaus St. Elisabeth Ravensburg: M. Sigg, M. Hartl; Sana Krankenhaus Süd Lübeck: B. Schneider; Klinikum Kas-
sel: J. Neuzner, C. Hansen; Klinikum Herford: R. Zotz. Hungary: Zala County Hospital Zalaegerszeg: G. Lupkovics, B. Nemeth; Semmelweis 
University AOK Budapest: B. Merkely, G. Szucs; Debreceni Egyetem Debrecen: I. Édes, R. Kolozsvári; Szegedi Tudományegyetem Szeged: T. Forster, 
A. Makai, L. Sághy. Poland: Szpital Wolski, Warsaw: D. Wojciechowski, M. Kowalewski, T. Gdowski, T. Roman; Silesian Center for Heart 
Disease, Zabrze: M. Zembala, Z. Kalarus, B. Sredniawa, E. Markowicz; Pomorska Akademia Med. Szczecin: C. Kornacewicz-Jach, J. Kazmier-
czak, R. Rzeuski; SPSK Academii Medycznej Białystok: W. Musial, J. Paruk, M. Witkowski; Szpital Uniwersytecki im. A. Jurasza Bydgoszcz: J. Ku-
bica, W. Krupa, S. Sielski, T. Fabiszak; Samodzielny Publiczny Centralny Szpital Kliniczny Warsaw: G. Opolski, P. Stolarz, A. Oręziak; I Klinika 
Kardiologii Gornoslaskie Centrum Medyczne Katowice: M. Trusz-Gluza, W. Orszulak, A. Filipecki, W. Kwasniewski, D. Kawecka; SP Wojewodzki 
Szpital Szczecin: M. Kurowski, T. Rozpara, W. Plewik; SPSK Nr 7 Gornoslaskie Centrum Medyczne Katowice: W. Kargul, K. Snajder, K. Goscinska-
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF DEBRECEN on April 29, 2010 . 
n engl j med 361;15 nejm.org october 8, 20091436
Defibrillator Implantation Early after Myocardial Infarction
Bis, K. Maslankiewicz; Szpital Miejski, Gdynia: P. Miekus, M. Szołkiewicz, M. Konarzewski; Krakowski Szpital Spec. im. Jana Pawla II: J. Lela-
kowsky, J. Bednarek; Szpital Wojewodzki im. Jana Pawla II Zamosc: A. Kleinrok, P. Dabrowski, B. Obszanski; Sp. Zakladem Opieki Zdrowotnej 
Opole: W. Pluta, G. Hordynski, M. Jedryszczak; Wojewodzki Szpital Sp. Olsztyn: J. Gorny, T. Godlewski; Uniwersytecki Szpital Kliniczny Nr 2 Lodz: 
A. Lubinski, A. Bissinger; CSK MSWiA, Warsaw: R. Gil, J. Kusnierz; Instytutem Kardiologii Warsaw: H. Szwed, A. Maciag, K. Gepner; 4 
Wojskowy Szpital Wroclaw: P. Ponikowski, D. Jagielski; Medical University of Poznan: A. Cieslinski, P. Mitkowski; Uniwersytecki Szpital Kliniczny 
Nr 3 Lodz: J. Goch, J. Ruta; Szpital Uniwersytecki Krakow: K. Kawecka-Jaszcz, M. Jastrzebski; SPSK 4 Lublin: T. Widomska-Czekajska, K. 
Poleszak, A. Glowniak, M. Dziduszko; SPSK Nr 1 AM w Gdansku: A. Rynkiewicz, W. Sobiczewski, M. Kempa; Szpital Wojewodzki 2 Rzeszow: 
J. Kuzniar, K. Dudek. Russia: A.L. Myasnikov Institute of Clinical Cardiology Moscow: E. Chazov, E. Kuchinskaya; City Hospital Nr 2, St. Petersburg: 
D. Lebedev. Slovak Republic: Slovak Institute of Heart and Vascular Diseases, Bratislava: P. Margitfalvi, R. Hatala. Data and Safety Monitoring 
Board: A. Hjalmarson (chair), L. Kappenberger, N. Victor. Steering Committee: Principal investigators: D. Andresen, J. Senges, G. Stein-
beck; Members: E. Hoffmann, K. Seidl, J. Brachmann, A. Lubinski. Adverse Event Committee: M. Rosenqvist (chair), M. Block, W. Schöls, 
B. Sredniawa. Data Verification Committee: U. Dorwarth, F. Gindele, B. Mark. Statistics: K. Wegscheider. Data Coordination Center: 
Oncology Services Europe, Munich.
References
Solomon SD, Zelenkofske S, McMur-1. 
ray JJ, et al. Sudden death in patients with 
myocardial infarction and left ventricular 
dysfunction, heart failure, or both. N Engl 
J Med 2005;352:2581-8.
Adabag AS, Therneau TM, Gersh BJ, 2. 
Weston SA, Roger VL. Sudden death after 
myocardial infarction. JAMA 2008;300: 
2022-9.
Køber L, Torp-Pedersen C. Clinical 3. 
characteristics and mortality of patients 
screened for entry into the Trandolapril 
Cardiac Evaluation (TRACE) study. Am J 
Cardiol 1995;76:1-5.
Amiodarone Trials Meta-Analysis In-4. 
vestigators. Effect of prophylactic amio-
darone on mortality after acute myocar-
dial infarction and in congestive heart 
failure: meta-analysis of individual data 
from 6500 patients in randomized trials. 
Lancet 1997;350:1417-24.
Jordaens L, Tavernier R, the MIRRACLE 5. 
Investigators. Determinants of sudden 
death after discharge from hospital for 
myocardial infarction in the thrombolytic 
era. Eur Heart J 2001;22:1214-25.
The Antiarrhythmics versus Implant-6. 
able Defibrillators (AVID) Investigators. 
A comparison of antiarrhythmic-drug ther-
apy with implantable defibrillators in pa-
tients resuscitated from near-fatal ventric-
ular arrhythmias. N Engl J Med 1997;337: 
1576-83.
Moss AJ, Zareba W, Hall WJ, et al. 7. 
Prophylactic implantation of a defibrilla-
tor in patients with myocardial infarction 
and reduced ejection fraction. N Engl J 
Med 2002;346:877-83.
Bardy GH, Lee KL, Mark DB, et al. 8. 
Amiodarone or an implantable cardio-
verter–defibrillator for congestive heart 
failure. N Engl J Med 2005;352:225-37.
Hohnloser SH, Kuck KH, Dorian P, et 9. 
al. Prophylactic use of an implantable 
cardioverter–defibrillator after acute myo-
cardial infarction. N Engl J Med 2004;351: 
2481-8.
Bigger JT Jr, Fleiss JL, Kleiger R, et al. 10. 
The relationships among ventricular ar-
rhythmias, left ventricular dysfunction, 
and mortality in the 2 years after myocar-
dial infarction. Circulation 1984;69:250-8.
Gottlieb SS, McCarter RJ, Vogel RA. 11. 
Effect of beta-blockade on mortality 
among high-risk and low-risk patients 
after myocardial infarction. N Engl J Med 
1998;339:489-97.
Hjalmarson A, Gilpin EA, Kjekshus J, 12. 
et al. Influence of heart rate on mortality 
after acute myocardial infarction. Am J 
Cardiol 1990;65:547-53.
Disegni E, Goldbourt U, Reicher-Reiss 13. 
H, et al. The predictive value of admission 
heart rate on mortality in patients with 
acute myocardial infarction. J Clin Epide-
miol 1995;48:1197-205.
Cheema AN, Sheu K, Parker M, Kadish 14. 
AH, Goldberger JJ. Nonsustained ventric-
ular tachycardia in the setting of acute 
myocardial infarction: tachycardia charac-
teristics and their prognostic implications. 
Circulation 1998;98:2030-6.
Andresen D, Steinbeck G, Brügge-15. 
mann T, et al. Risk stratification follow-
ing myocardial infarction in the throm-
bolytic era: a two-step strategy using 
noninvasive and invasive methods. J Am 
Coll Cardiol 1999;33:131-8.
Andresen D, Steinbeck G, Brügge-16. 
mann T, et al. Fast non-sustained ventric-
ular tachycardias predict sudden cardiac 
death in patients following myocardial 
infarction. Eur Heart J 1999;20:Suppl:232.
Steinbeck G, Andresen D, Senges J, 17. 
Hoffmann E, Seidl KH, Brachmann J. Im-
mediate Risk-Stratification Improves Sur-
vival (IRIS): study protocol. Europace 2004; 
6:392-9.
O’Brien PC, Fleming TR. A multiple 18. 
testing procedure for clinical trials. Bio-
metrics 1979;35:549-56.
Lan KKG, DeMets DL. Discrete se-19. 
quential boundaries for clinical trials. 
Biometrika 1983;70:659-63.
Whitehead J. The design and analysis 20. 
of sequential clinical trials. 2nd ed. Rev. 
New York: Wiley, 1997.
Kaplan EL, Meier P. Nonparametric 21. 
estimation from incomplete observations. 
J Am Stat Assoc 1958;53:457-81.
Mantel N. Evaluation of survival data 22. 
and two new rank order statistics arising 
in its consideration. Cancer Chemother 
Rep 1966;50:163-70.
ADDPLAN Adaptive designs — plans 23. 
and analysis, user’s guide, release 4. Co-
logne, Germany: ADDPLAN GmbH, 2007.
Fine JP, Gray RJ. A proportional haz-24. 
ards model for the subdistribution of a 
competing risk. J Am Stat Assoc 1999;94: 
496-509.
Poole JE, Johnson GW, Hellkamp AS, 25. 
et al. Prognostic importance of defibrilla-
tor shocks in patients with heart failure. 
N Engl J Med 2008;359:1009-17.
Moss AJ, Greenberg H, Case RB, et al. 26. 
Long-term clinical course of patients af-
ter termination of ventricular tachyar-
rhythmia by an implanted defibrillator. 
Circulation 2004;110:3760-5.
Goldenberg I, Moss AJ, Hall WJ, et al. 27. 
Causes and consequences of heart failure 
after prophylactic implantation of a defi-
brillator in the Multicenter Automatic De-
fibrillator Implantation Trial II. Circula-
tion 2006;113:2810-7.
Daubert JP, Zareba W, Cannom DS, et 28. 
al. Inappropriate implantable cardioverter-
defibrillator shocks in MADIT II: fre-
quency, mechanisms, predictors, and sur-
vival impact. J Am Coll Cardiol 2008;51: 
1357-65.
Ezekowitz JA, Kaul P, Bakal JA, Arm-29. 
strong PW, Welsh RC, McAlister FA. De-
clining in-hospital mortality and increas-
ing heart failure incidence in elderly 
patients with first myocardial infarction. 
J Am Coll Cardiol 2009;53:13-20.
Rosenbaum DS, Jackson LE, Smith 30. 
JM, Garan H, Ruskin JN, Cohen RJ. Elec-
trical alternans and vulnerability to ven-
tricular arrhythmias. N Engl J Med 1994; 
330:235-41.
Bauer A, Kantelhardt JW, Barthel P, 31. 
et al. Deceleration capacity of heart rate 
as a predictor of mortality after myocar-
dial infarction: cohort study. Lancet 2006; 
367:1674-81.
Copyright © 2009 Massachusetts Medical Society.
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF DEBRECEN on April 29, 2010 . 
